Abstract:Human mitochondrial ornithine transporter-1 is reported in coupling with the hyperornithinemia-hyperammonemia-homocitrullinuria (HHH) syndrome, which is a rare autosomal recessive disorder. For in-depth understanding of the molecular mechanism of the disease, it is crucially important to acquire the 3D structure of human mitochondrial ornithine transporter-1. Since no such structure is available in the current protein structure database, we have developed it via computational approaches based on the recent NMR structure of human mitochondrial uncoupling protein (Berardi MJ, Chou JJ, et al. Nature 2011, 476:109-113). Subsequently, we docked the ligand L-ornithine into the computational structure to search for the favorable binding mode. It was observed that the binding interaction for the most favorable binding mode is featured by six remarkable hydrogen bonds between the receptor and ligand, and that the most favorable binding mode shared the same ligand-binding site with most of the homologous mitochondrial carriers from different organisms, implying that the ligand-binding sites are quite conservative in the mitochondrial carriers family although their sequences similarity is very low with 20% or so. Moreover, according to our structural analysis, the relationship between the disease-causing mutations of human mitochondrial ornithine transporter-1 and the HHH syndrome can be classified into the following three categories: (i) the mutation occurs in the pseudo-repeat regions so as to change the region of the protein closer to the mitochondrial matrix; (ii) the mutation is directly affecting the substrate binding pocket so as to reduce the substrate binding affinity; (iii) the mutation is located in the structural region closer to the intermembrane space that can significantly break the salt bridge networks of the protein. These findings may provide useful insights for in-depth understanding of the molecular mechanism of the HHH syndrome and developing effective drugs against the disease.

Mutation in Transmembrane Domain 8 of Human Urate Transporter 1 Disrupts Uric Acid Recognition and Transport

Structural Insights into the Atomistic Mechanisms of Uric Acid Recognition and Translocation of Human Urate Anion Transporter 1

Structural basis for the transport and substrate selection of human urate transporter 1

Mechanisms of urate transport and uricosuric drugs inhibition in human URAT1

Structural Insights into the Mechanisms of Urea Permeation and Distinct Inhibition Modes of Urea Transporters

Transport mechanism and structural pharmacology of human urate transporter URAT1

Molecular mechanisms of uric acid transport by the native human URAT1 and its inhibition by anti-gout drugs

Molecular basis of the urate transporter URAT1 inhibition by gout drugs

Solving the Mysteries of Urate Transport: Structural Insights into GLUT9 and URAT1

Structural basis for urate recognition and apigenin inhibition of human GLUT9

Expression, Purification, and Structural Insights for the Human Uric Acid Transporter, GLUT9, Using the Xenopus laevis Oocytes System

Novel urate transporter 1 (URAT1) inhibitors: a review of recent patent literature (2016-2019).

Role of Transmembrane Domain 10 for the Function of Organic Anion Transporting Polypeptide 1B1

A System for Discovering Novel Uricosurics Targeting Urate Transporter 1 Based on In Vitro and In Vivo Modeling

Insights into the mutation-induced HHH syndrome from modeling human mitochondrial ornithine transporter-1

Structural Implications of A G170r Mutation of Alanine:Glyoxylate Aminotransferase That is Associated with Peroxisome-To-Mitochondrion Mistargeting

Effect of Mutations at Y358 and S548 on OATP1B3 Mediated Transport

Structure and Permeation Mechanism of a Mammalian Urea Transporter.

Structure of eukaryotic purine/H+ symporter UapA suggests a role for homodimerization in transport activity

Discovery Of A Flexible Triazolylbutanoic Acid As A Highly Potent Uric Acid Transporter 1 (Urat1) Inhibitor

Recent Advances on Uric Acid Transporters